27 results
424B5
IFRX
InflaRx N.V.
12 Jul 23
Prospectus supplement for primary offering
12:00am
goal is to maintain and further advance our leadership position within the anti-C5a and anti-C5aR complement space, delivering first-in-class autoimmune … induced acute respiratory distress syndrome, or virally induced ARDS.
Solidify and continue to expand the breadth of our leadership position in the anti
F-3
IFRX
InflaRx N.V.
30 Jun 23
Shelf registration (foreign)
4:06pm
about and the development status of our current pipeline of product candidates.
Our Strategy
Our goal is to maintain and further advance our leadership … , or virally induced ARDS.
Solidify and continue to expand the breadth of our leadership position in the anti-C5a/anti-C5aR space by leveraging the full
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development
424B5
xdrkb9vp
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
5w0h91eu49 8bue
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.3
m7jqrb 0jn3
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
m2u4phiwtdd
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
vitx9urv
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
424B5
i71uqafz2
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
cwpwwcv3rjn qu9
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
EX-99.3
e1w1p tuht
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
24zzdc6ofygzjcz
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
424B5
lofuy1
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
enegx0 9wl2
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
gxzpiv9g
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am